Grand Pharmaceutical Group Limited (HK:0512)
:0512
Top Page
Grand Pharmaceutical Group Limited
(0512)
Select Model
Select Model
Rating:73Outperform
Price Target:
HK$8.50
▲(8.97% Upside)
Action:UpgradedDate:09/13/25
Grand Pharmaceutical Group Limited demonstrates strong financial performance with robust revenue growth and a solid balance sheet. However, the recent decline in EBIT margin and mixed technical indicators suggest caution. The valuation is fair, offering potential for growth if operational efficiencies are enhanced. The absence of recent earnings call data and corporate events limits additional insights.
Positive Factors
Consistent revenue growth
Grand Pharm shows multi-year top-line expansion (CAGR ~12%, recent revenue growth ~10.6%). Durable revenue growth supports scaling hospital access, funds R&D and registrations, and reduces reliance on single products—underpinning sustainable competitive positioning over the next 2–6 months.
Negative Factors
Collapsed EBIT margin
An EBIT margin falling to ~0% signals material operating-profit pressure. That erosion reduces internal funding for R&D and commercialization, narrows flexibility on tender pricing, and increases dependence on scale or cost cuts to restore sustainable operating profitability over several quarters.
Read all positive and negative factors
Positive Factors
Negative Factors
Consistent revenue growth
Grand Pharm shows multi-year top-line expansion (CAGR ~12%, recent revenue growth ~10.6%). Durable revenue growth supports scaling hospital access, funds R&D and registrations, and reduces reliance on single products—underpinning sustainable competitive positioning over the next 2–6 months.
Read all positive factors
Grand Pharmaceutical Group Limited (0512) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$25.63B
Dividend Yield3.13%
Average Volume (3M)9.26M
Price to Earnings (P/E)22.2
Beta (1Y)0.76
Revenue Growth10.56%
EPS Growth-13.58%
CountryHK
Employees11,987
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)0.02
Shares Outstanding3,549,571,000
10 Day Avg. Volume7,622,050
30 Day Avg. Volume9,255,379
Financial Highlights & Ratios
PEG Ratio0.23
Price to Book (P/B)1.02
Price to Sales (P/S)1.44
P/FCF Ratio13.17
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$12.00Price Target Upside53.85% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)0.66
Revenue Forecast (FY)HK$13.39B
Grand Pharmaceutical Group Limited Business Overview & Revenue Model
Company Description
Grand Pharmaceutical Group Limited, an investment holding company, engages in the research and development, manufacture, and sale of pharmaceutical preparations and medical devices, biotechnology and healthcare products, and pharmaceutical raw mat...
How the Company Makes Money
Grand Pharmaceutical Group Limited generates revenue through multiple streams, primarily through the sale of its pharmaceutical products and medical devices. The company leverages its robust research and development capabilities to bring novel and...
Grand Pharmaceutical Group Limited Financial Statement Overview
Summary
Income Statement
85
Very Positive
Balance Sheet
78
Positive
Cash Flow
82
Very Positive
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 11.70B | 11.64B | 10.53B | 9.56B | 8.60B | 6.35B |
| Gross Profit | 6.75B | 6.74B | 6.52B | 5.95B | 5.25B | 4.04B |
| EBITDA | 2.80B | 3.39B | 2.97B | 3.09B | 3.10B | 2.41B |
| Net Income | 2.08B | 2.47B | 1.88B | 2.08B | 2.40B | 1.79B |
Balance Sheet | ||||||
| Total Assets | 26.47B | 24.99B | 22.52B | 22.37B | 21.06B | 16.98B |
| Cash, Cash Equivalents and Short-Term Investments | 1.81B | 3.14B | 2.47B | 2.48B | 2.87B | 2.39B |
| Total Debt | 4.61B | 4.44B | 3.40B | 4.48B | 3.65B | 2.39B |
| Total Liabilities | 9.18B | 8.47B | 7.24B | 8.16B | 7.61B | 5.64B |
| Stockholders Equity | 17.15B | 16.47B | 15.16B | 14.14B | 13.39B | 11.24B |
Cash Flow | ||||||
| Free Cash Flow | 1.07B | 1.28B | 1.93B | 245.79M | 1.49B | 1.31B |
| Operating Cash Flow | 1.66B | 1.90B | 2.42B | 1.92B | 2.12B | 1.78B |
| Investing Cash Flow | -1.07B | -2.00B | -515.75M | -2.58B | -1.77B | -2.05B |
| Financing Cash Flow | -906.29M | 29.96M | -1.89B | 464.49M | -333.17M | 899.79M |
Grand Pharmaceutical Group Limited Technical Analysis
Neutral
7.80
Price Trends
7.44
Negative
7.80
Negative
8.31
Negative
Market Momentum
-0.12
Negative
51.87
Neutral
86.57
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:0512, the sentiment is Neutral. The current price of 7.8 is above the 20-day moving average (MA) of 7.05, above the 50-day MA of 7.44, and below the 200-day MA of 8.31, indicating a neutral trend. The MACD of -0.12 indicates Negative momentum. The RSI at 51.87 is Neutral, neither overbought nor oversold. The STOCH value of 86.57 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for HK:0512.
Grand Pharmaceutical Group Limited Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
73 Outperform | HK$25.63B | 22.15 | 7.26% | 3.13% | 10.56% | -13.58% | |
71 Outperform | HK$20.80B | 9.66 | 12.63% | 5.11% | 0.39% | 4.94% | |
70 Outperform | HK$31.78B | 11.61 | 14.47% | 4.09% | -0.45% | 9.00% | |
63 Neutral | HK$34.96B | 19.33 | 8.60% | 2.26% | 11.78% | 19.06% | |
61 Neutral | HK$39.39B | 6.37 | 7.91% | 2.95% | ― | ― | |
55 Neutral | HK$20.55B | 4.97 | 41.38% | ― | -1.78% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
HK:0512
Grand Pharmaceutical Group Limited
7.22
1.88
35.21%
HK:0013
HUTCHMED (China)
23.56
4.48
23.48%
HK:3933
The United Laboratories International Holdings
10.54
-0.25
-2.29%
HK:0867
China Medical System Holdings
14.33
7.38
106.19%
HK:1513
Livzon Pharmaceutical Group
29.20
4.54
18.40%
HK:3320
China Resources Pharmaceutical Group Ltd.
6.27
1.70
37.08%
Grand Pharmaceutical Group Limited Corporate Events
Grand Pharmaceutical Clarifies Valuation Basis for RMB316 Million API Assets Acquisition
Feb 3, 2026
Grand Pharmaceutical Group Limited has issued a supplemental and clarification announcement regarding its previously disclosed connected transaction to acquire the entire equity interests in Hebei Yuanda Jiufu Biotechnology Co., Ltd. and Baoding J...
Grand Pharmaceutical Wins NMPA Acceptance for Prostate Cancer Imaging Drug TLX591-CDx
Jan 19, 2026
Grand Pharmaceutical Group Limited has announced that China’s National Medical Products Administration has accepted the new drug application for TLX591-CDx (Illuccix), its innovative radionuclide-drug conjugate for diagnosing prostate cancer...
Grand Pharmaceutical to Acquire Two Biotech and Fine Chemical Units in RMB316 Million Connected Deal
Dec 31, 2025
Grand Pharmaceutical Group Limited has announced that its subsidiary Hubei Yuanda will acquire 100% of the equity interests in Hebei Yuanda Jiufu Biotechnology Co., Ltd. and Baoding Jiahe Fine Chemical Co., Ltd. for a total consideration of RMB316...
Grand Pharmaceutical Wins China Nod for World’s First Adrenaline Nasal Spray
Dec 29, 2025
Grand Pharmaceutical Group has announced that Neffy, the world’s first adrenaline nasal spray for emergency treatment of type I allergic reactions, has obtained a drug registration certificate from China’s National Medical Products Adm...
Grand Pharmaceutical Secures China Rights to World’s First Adrenaline Nasal Spray
Dec 23, 2025
Grand Pharmaceutical Group has entered into a product cooperation agreement with Pediatrix Therapeutics Technology (Shanghai) to secure exclusive commercialization rights for Neffy, the world’s first adrenaline nasal spray for emergency trea...
Grand Pharmaceutical’s TLX591-CDx Hits Phase III Goal in China, Bolstering Nuclear Medicine Push
Dec 21, 2025
Grand Pharmaceutical Group has reported that its radionuclide-drug conjugate TLX591-CDx, marketed globally as Illuccix for prostate cancer diagnosis, has successfully met the primary endpoint in a Phase III clinical trial in China, demonstrating h...
Grand Pharmaceutical’s GPN01530 Gains FDA Approval for Clinical Trials
Dec 17, 2025
Grand Pharmaceutical Group Limited has announced FDA approval for clinical trials of its newly developed radionuclide-drug conjugate, GPN01530, aimed at diagnosing solid tumors. This milestone highlights the company’s progression in nuclear ...
Grand Pharmaceutical’s TCM for Depression Achieves Clinical Milestone
Dec 8, 2025
Grand Pharmaceutical Group Limited announced the successful completion of Phase II clinical trials for its innovative traditional Chinese medicine, GPN01360, aimed at treating depression. The trial demonstrated significant efficacy and safety, mar...
Grand Pharmaceutical Updates Directors’ Emoluments in Annual Reports
Dec 4, 2025
Grand Pharmaceutical Group Limited has issued a supplemental announcement concerning the disclosure of directors’ and employees’ emoluments in its 2021 and 2022 annual reports. The update provides detailed information on the fees, sala...
Glenmark Pharmaceutical’s Ryaltris® Nasal Spray Approved for Chinese Market
Nov 10, 2025
Grand Pharmaceutical Group Limited announced the approval of Ryaltris® Nasal Spray for commercialization in China, a significant milestone in their respiratory segment. This innovative combination product, developed by Glenmark, addresses the...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.